Radiopharma company Pentixapharm to be spun off as it acquires Glycotope

Clinical-stage radiopharmaceutical firm Pentixapharm, owned by the Eckert & Ziegler Group, is acquiring the target discovery business of Glycotope and preparing to spin off into a separate company. This move includes Glycotope’s intellectual property, data, laboratories, and equipment. Pentixapharm is developing therapies for hypertension and CNS lymphoma.